On December20,2020, Israel initiated a national vaccination program against COVID-19.National and international vaccine guide lines did not preclude patients who have previously been diagnosed with Guillian-Barré Syndrome (GBS) from receiving the COVID-19 vaccine. However, previous association between vaccines and GBS raises the level of caution and hesitancy among clinicians and patients regarding administering the vaccine. The aim of this study was to establish rates of GBS relapse among Pfizer-BioNTech BNT162b2 vaccine receivers